» Articles » PMID: 17936897

Design Maps for Nanoparticles Targeting the Diseased Microvasculature

Overview
Journal Biomaterials
Date 2007 Oct 16
PMID 17936897
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Systemically administered ligand-coated nanoparticles have been proved to recognize biological targets in-vivo. This can provide breakthrough solutions for the early detection, imaging and cure of diseases. In cardiovascular applications, nanoparticles have been targeted directly to the diseased vasculature, and such delivery approach is becoming increasingly popular even in cancer research, supported by the growing body of evidences on the biological differences between normal and tumor vasculature. This work focuses on the optimal design of nanoparticles for vascular targeting throughout mathematical modeling. Such nanoparticles should be engineered so as to recognize specifically and adhere firmly to the diseased vessel walls withstanding the hydrodynamic dislodging forces and control uptake by the endothelial cells. A stochastic approach for predicting the adhesion strength of nanoparticles to a cell layer under flow has been coupled to a mathematical model for the receptor-mediated endocytosis of nanoparticles. The main geometrical, biophysical and biological parameters governing both events have been identified and their relative importance highlighted. Three different states for the particle/cell system have been predicted, namely no adhesion, adhesion with no endocytosis and adhesion with endocytosis, based upon the geometrical and biophysical properties of the particle and the biological conditions at the site of adhesion. Design maps have been generated to be used as a preliminary reference for choosing the properties of the nanoparticle as a function of physiological parameters, as the wall shear stress and the receptors surface density, at the site of desired adhesion within the target vasculature.

Citing Articles

Rational nanoparticle design: Optimization using insights from experiments and mathematical models.

Richfield O, Piotrowski-Daspit A, Shin K, Saltzman W J Control Release. 2023; 360:772-783.

PMID: 37442201 PMC: 10529591. DOI: 10.1016/j.jconrel.2023.07.018.


Quantifying and controlling bond multivalency for advanced nanoparticle targeting to cells.

Makhani E, Zhang A, Haun J Nano Converg. 2021; 8(1):38.

PMID: 34846580 PMC: 8633263. DOI: 10.1186/s40580-021-00288-1.


Elucidating the rheological implications of adding particles in blood.

Stephanou P Rheol Acta. 2021; 60(10):603-616.

PMID: 34334825 PMC: 8313244. DOI: 10.1007/s00397-021-01289-x.


Model Particulate Drug Carriers Modulate Leukocyte Adhesion in Human Blood Flows.

Kelley W, Onyskiw P, Fromen C, Eniola-Adefeso O ACS Biomater Sci Eng. 2021; 5(12):6530-6540.

PMID: 33417805 PMC: 9588176. DOI: 10.1021/acsbiomaterials.9b01289.


Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity.

Atukorale P, Raghunathan S, Raguveer V, Moon T, Zheng C, Bielecki P Cancer Res. 2019; 79(20):5394-5406.

PMID: 31431457 PMC: 6801091. DOI: 10.1158/0008-5472.CAN-19-0381.